Lateral femoral cutaneous nerve block does not demonstrate analgesic efficacy in THA .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2016;4(12):4 BMC Anesthesiol. 2016 Mar 23;16(1):21120 patients scheduled for total hip arthroplasty were randomized to receive either an ultrasound-guided lateral femoral cutaneous nerve (LFNC) block or placebo, in addition to standard oral paracetamol and ibuprofen, and oxycodone for breakthrough pain. The purpose of this study was to evaluate if the use of a LFCN block significantly reduce pain scores and opioid consumption within the first 24 hours postoperative in comparison to placebo. No significant difference between groups in pain score or opioid consumption were observed.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Ja = 1
Ungewiss = 0.5
Nicht relevant = 0
Nein = 0
Die Bewertung der Berichtskriterien bewertet die Transparenz, mit der die Autoren die methodischen und studienspezifischen Merkmale der Studie in der Veröffentlichung angeben. Die Bewertung ist in fünf Kategorien unterteilt, die im Folgenden vorgestellt werden.
4/4
Randomization
3/4
Outcome Measurements
4/4
Inclusion / Exclusion
4/4
Therapy Description
4/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
Der Fragilitätsindex ist ein Instrument, das bei der Interpretation signifikanter Ergebnisse hilft und ein Maß für die Stärke eines Ergebnisses liefert. Der Fragilitätsindex gibt die Anzahl der aufeinanderfolgenden Ereignisse an, die zu einem dichotomen Ergebnis hinzugefügt werden müssen, damit das Ergebnis nicht mehr signifikant ist. Eine kleine Zahl steht für ein schwächeres Ergebnis und eine große Zahl für ein stärkeres Ergebnis.
Warum wurde diese Studie jetzt benötigt?
Pain management following total hip arthroplasty is an important consideration in overall patient outcome. Current strategies aim to reduce opioid use in patients, particularly among elderly, who demonstrate poor tolerance to opioids. Peripheral nerve blocks, such as a femoral nerve block and fascia iliaca block, have demonstrated efficacy in limiting postoperative pain, but face the drawback of motor deficit, which in turn can delay mobilization and recovery. A more recent nerve block approach for postoperative analgesia in THA is a lateral femoral cutaneous nerve block, though randomized controlled trials on its use in this setting are lacking.
Was war die wichtigste Forschungsfrage?
Does a lateral femoral cutaneous nerve block, when used in conjunction with a basic analgesic regimen of paracetamol and ibuprofen, significantly reduce pain on movement at 4 hours after total hip arthroplasty, when compared to a placebo block?
- At 4 hours, there was no significant difference in VAS pain score on movement between the LFCN block group and the placebo group (Mean difference: -5mm [95%CI -15, 5]) (p=0.41).
- There were also no reported significant differences in pain at rest or pain on movement at any time point between groups (p-values not reported). Data on pain scores at 8 and 12 hour time points was excluded due to difficulty in obtaining data at those points.
- There was no significant difference in cumulative 24-hour opioid consumption between the LFCN block group (Median: 7mg [2-13]) and the placebo group (6mg [2-9]) (p=0.12),
- Time to first request of opioid analgesia did not significantly differ between the LFCN block group (253min [144-379]) and the placebo group (237min [155-380]) (p=1.0).
- Ambulation score and time to ambulation did not significantly differ between groups (p=0.26 and 0.69, respectively).
- Length of hospital stay did not significantly differ between the LFCN block group (49+/-10 hours) and the placebo group (50+/-20 hours) (p=0.53).
- No treatment related adverse events were documented in either group.
Was sollte ich mir besonders merken?
In total hip arthroplasty, a lateral femoral cutaneous nerve block did not significantly reduce pain scores or opioid consumption over the first 24 hours postoperative in patients managed with standardized oral analgesia and opioid analgesia for breakthrough pain.
Wie wird sich dies auf die Behandlung meiner Patienten auswirken?
The results of this study suggest that the use of a lateral femoral cutaneous nerve block administered postoperatively may not demonstrate analgesic efficacy for patients undergoing total hip arthroplasty.
HAFTUNGSAUSSCHLUSS
Der Inhalt dieser Seite dient nur zu Informationszwecken und ist nicht als Ersatz für professionelle medizinische Beratung, Diagnose oder Behandlung gedacht. Wenn Sie eine medizinische Behandlung benötigen, wenden Sie sich immer an Ihren Arzt oder suchen Sie die nächstgelegene Notaufnahme auf. Die Meinungen, Überzeugungen und Standpunkte, die von den Personen auf dieser Seite geäußert werden, spiegeln nicht die Meinungen, Überzeugungen und Standpunkte von OrthoEvidence wider.